| Bioactivity | Lutetium (177lu) vipivotide tetraxetanis the 177lu labeled Lutetium combinded with Vipivotide tetraxetan (DOTA-VIP, a DOTA labled vasoactive intestinal peptide)[1]. |
| Invitro | 氢、碳和其他元素的稳定重同位素已被纳入药物分子中，主要作为药物开发过程中定量的示踪剂。氘化引起了人们的关注，因为它可能影响药物的药代动力学和代谢谱[1]。 |
| Name | Lutetium (177lu) vipivotide tetraxetan |
| CAS | 1703749-62-5 |
| Formula | C49H68177LuN9O16 |
| Molar Mass | 1216.06 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. |
Lutetium (177lu) vipivotide tetraxetan
CAS: 1703749-62-5 F: C49H68177LuN9O16 W: 1216.06
Lutetium (177lu) vipivotide tetraxetanis the 177lu labeled Lutetium combinded with Vipivotide tetraxetan (DOTA-VIP, a DO
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.